[Elexacaftor, Tezacaftor and Ivacaftor: immediate efficacy evaluation using home spirometry]
M Thimmesch1, M Boulay2, E Defgnée2
1Unité de pneumologie pédiatrique, centre de mucoviscidose liégeois, CHC MontLégia, boulevard Patience et Beaujonc 2, 4000 Liège, Belgique.
Revue Des Maladies Respiratoires
|January 21, 2025
Summary
Triple combination therapy (Elexacaftor, Tezacaftor, Ivacaftor) significantly improved lung function and respiratory symptoms in cystic fibrosis patients starting on day 6. Early treatment side effects were noted but manageable with home spirometry monitoring.
Area of Science:
- Pulmonology
- Pharmacology
- Medical Technology
Context:
- Cystic Fibrosis (CF) is a genetic disorder affecting lungs and other organs.
- Triple combination therapy (Elexacaftor, Tezacaftor, Ivacaftor - ETI) shows promise for CF treatment.
- Limited data exist on the initial 14-day impact of ETI therapy.
Purpose:
- To prospectively evaluate the early (14-day) effects of ETI on pulmonary function and respiratory symptoms in CF patients.
- To assess the feasibility and quality of home spirometry monitoring during the initiation of ETI treatment.
Summary:
- A prospective study monitored 20 CF patients (≥12 years) initiating ETI therapy using daily home spirometry and respiratory symptom scores for 14 days.
- Significant improvements in FEV1 (Forced Expiratory Volume in 1 second) were observed from Day 6 onwards.
- Respiratory symptom scores initially worsened on Day 1 but improved from Day 6; side effects were most common in the first four days.
Impact:
- ETI therapy demonstrates significant respiratory benefits detectable from the first week of treatment.
- Daily home spirometry is a valuable tool for monitoring CF patients on ETI, provided adequate training.
- Findings provide crucial insights into the rapid onset of ETI's therapeutic effects and patient-reported outcomes.
Related Concept Videos
01:30Asthma-IV: Diagnostic and Management
2.5K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.5K
01:27Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies
2.5K
Assessing and diagnosing Chronic Obstructive Pulmonary Disease (COPD) involves a detailed approach that includes a comprehensive review of medical history, physical examination, and a variety of diagnostic tests. This thorough evaluation is essential to ensure an accurate diagnosis and guide effective management strategies.
Medical History
Medical History
2.5K
01:25Pulmonary Function Tests
297
Pulmonary Function Tests (PFTs)
Pulmonary Function Tests are crucial diagnostic tools for assessing respiratory function, particularly in patients with chronic respiratory disorders. They comprehensively evaluate lung volumes, ventilatory function, breathing mechanics, diffusion, and gas exchange. These tests help diagnose pulmonary diseases and play a significant role in monitoring disease progression, evaluating disability, and assessing response to therapy.
PFTs involve using a spirometer, a...
Pulmonary Function Tests are crucial diagnostic tools for assessing respiratory function, particularly in patients with chronic respiratory disorders. They comprehensively evaluate lung volumes, ventilatory function, breathing mechanics, diffusion, and gas exchange. These tests help diagnose pulmonary diseases and play a significant role in monitoring disease progression, evaluating disability, and assessing response to therapy.
PFTs involve using a spirometer, a...
297